Provigil Articles
US Drug & Biotech Firms Post Quarterly Results
14 August 1997
Cephalon Chief On FDA Panel Decision
26 May 1997
FDA Panel Rejects Myotrophin Again
19 May 1997
NEW YORK STOCK COMMENT
20 January 1997
Cephalon Files Modafinil Application In USA
13 January 1997
Cephalon Sees Two NDA Filings By Year-End
21 October 1996
Positive Results From Second PhII Modafinil Study
25 March 1996
Modafinil Filed In Canada By End-96?
4 March 1996
Modafinil Proves Effective In Narcolepsy
19 February 1996
Cephalon: modafinil
9 October 1995
Results US Biopharmaceutical Firms Progress In Second Quarter
4 September 1995
Eight-Year-Old Cephalon Integrates For Success
22 May 1995
New Chemical Entities Round-Up For 1994
6 February 1995
Lafon Launches Modiodal For Narcolepsy
17 October 1994
Glaxo Close To French Imigran Deal?
12 September 1994
France To Ease Key Drug Prescribing
22 August 1994
Cephalon Starts Phase III Modafinil Trials
15 August 1994
MYOTROPHIN TESTED FOR POST-POLIO SYNDROME
16 May 1994
US MODAFINIL TRIAL STARTED
6 September 1993
SMALLER US COMPANIES POST MIXED RESULTS
16 August 1993
MERCKLE GAINS LICENSE FROM LAFON
26 July 1993
CEPHALON FILES US IND FOR MODAFINIL
19 July 1993
CEPHALON RESEARCH EFFORTS NEAR FRUITION
5 July 1993
US BIOTECH FIRMS POST GOOD 1st QTRs
17 May 1993
MODAFINIL APPROVED IN FRANCE
2 November 1992
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
